Irene Strassl

Linz, Austria

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

Chromosome 1q alterations in transplant-eligible multiple myeloma: clinical impact of copy number and co-occurring high-risk cytogenetic features.

Chromosome 1q alterations in transplant-eligible multiple myeloma: clinical impact of copy number and co-occurring high-risk cytogenetic features.

Journal: Frontiers in oncology
Published: May 31, 2026

Long-term follow-up of ruxolitinib pre-approval use in acute and chronic graft-versus-host disease.

Long-term follow-up of ruxolitinib pre-approval use in acute and chronic graft-versus-host disease.

Journal: Annals of hematology
Published: May 28, 2026

Infectious toxicities associated with bispecific antibodies and CAR-T Cells in multiple myeloma: a systematic review.

Infectious toxicities associated with bispecific antibodies and CAR-T Cells in multiple myeloma: a systematic review.

Journal: Annals of hematology
Published: May 04, 2026

Impact of Disease Biology and Bridging Strategy on Outcomes After CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma.

Impact of Disease Biology and Bridging Strategy on Outcomes After CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma.

Journal: Transplantation and cellular therapy
Published: April 25, 2026

Real-world outcomes of ide-cel and cilta-cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria.

Real-world outcomes of ide-cel and cilta-cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria.

Journal: British journal of haematology
Published: April 25, 2026

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.

Journal: Haematologica
Published: April 15, 2026

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma.

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma.

Journal: Bone marrow transplantation
Published: January 15, 2026

Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

Journal: Blood cancer discovery
Published: December 03, 2025

Rapid Hematological and Molecular Response to Pegylated Interferon in WHO-Defined Pre-Fibrotic Myelofibrosis.

Rapid Hematological and Molecular Response to Pegylated Interferon in WHO-Defined Pre-Fibrotic Myelofibrosis.

Journal: Cancers
Published: October 18, 2025

The impact of tacrolimus levels on acute GVHD and transplant outcomes in haploidentical hematopoietic stem cell transplantation: A retrospective analysis.

The impact of tacrolimus levels on acute GVHD and transplant outcomes in haploidentical hematopoietic stem cell transplantation: A retrospective analysis.

Journal: Cell transplantation
Published: August 14, 2025

Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Prolymphocytic Leukemia.

Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Prolymphocytic Leukemia.

Journal: Journal of clinical medicine
Published: March 16, 2025

Implementation of a one-tube flow cytometry panel for measurable residual disease detection in multiple myeloma patients in clinical routine.

Implementation of a one-tube flow cytometry panel for measurable residual disease detection in multiple myeloma patients in clinical routine.

Journal: Cytometry. Part B, Clinical cytometry
Published: December 11, 2024
Showing 1-12 of 25

Last Updated: 09/26/2026